DreaMed Diabetes
Petah Tiqva
About DreaMed Diabetes
DreaMed Diabetes is a medical device, SaaS company providing personalized diabetes treatment optimization solutions. The company was established in 2014, commercializing the first artificial pancreas technology which was published in the NEJM. Eversince, DreaMed Diabetes has been vigorously working on decision support tools in the diabetes management space and became the first and only company in the world to receive FDA clearance for a decision support system using data from CGM/SMBG and insulin pumps. We offer a clinically proven decision support system for insulin titration in type 1 diabetes patients. Our Advisor Pro software was created by diabetes professionals and is based on real-world experience, turbo-charged by artificial intelligence. Using it, any healthcare professional can analyze patient data in seconds and advise on the optimal treatment plan. By frequent titration changes and online monitoring, we allow patients better treatment thus by lowering their A1C levels and risk for complications. Using the Advisor Pro physicians and nurses can provide true patient-centered care and everyone can receive the same top-level of treatment – wherever they are and whoever their caregiver is.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $13.3M
- Last round: Series Unknown (Aug 2024)
- Website: dreamed-diabetes.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Diabetes, Enterprise Software, Health Care
Social Profiles
Canonical: https://fsome.com/organization/dreamed-diabetes-11076 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.